Response of Multiple Recurrent TaT1 Bladder Cancer to Intravesical Apaziquone (EO9): Comparative Analysis of Tumor Recurrence Rates

References

Page 1

	Year	Citations
A Prospective European Organization for Research and Treatment of Cancer Genitourinary Group Randomized Trial Comparing Transurethral Resection Followed by a Single Intravesical Instillation of Epirubicin or Water in Single Stage Ta, T1 Papillary Carcinoma of the Bladder Willem Oosterlinck, Karl H. Kurth, Fritz H. Schröder, The Journal of Urology	1993	366
Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Paul Workman PubMed Medicinal ChemistryBiosynthesisBioorganic ChemistryEnzyme ProfilingBiochemistry	1994	124
Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party) David A. Tolley, T. B. Hargreave, Philip H. Smith, BMJ Control GroupUrologySurgical OncologyUrological ResearchGenitourinary Cancer	1988	104
EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models Hans R. Hendriks, P. E. Pizao, Dan Berger, European Journal of Cancer Tumor BiologyPreclinical ModelsMedicineBone Marrow ToxicityAnti-cancer Agent	1993	104
Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours BP Cronin British Journal of Cancer Drug TargetingPreclinical Drug EvaluationMedicinePharmacologyAvascular Regions	1998	78
Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker Response Antoine G. van der Heijden, Paula M.J. Moonen, Erik B. Cornel, The Journal of Urology	2006	71
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group Luc Dirix, Jim Cassidy, Ron Epelbaum, European Journal of Cancer Surgical OncologyBreast OncologyGastrointestinal OncologyMedicineGastroenterology	1996	60
A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9 Guzanfar A. Choudry, P A Hamilton Stewart, John A. Double, British Journal of Cancer	2001	52
Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer Rajiv Puri, Victor Palit, Paul M. Loadman, The Journal of Urology	2006	45
A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC Early Clinical Studies Group (ECSG) Nicholas Pavlidis, Axel‐R. Hanauske, Teresa Gamucci, Annals of Oncology Non-small-cell Lung CancerNovel Indoloquinone Eo9MedicineCancer ManagementPharmacology	1996	43

Page 1